• Ángel Martínez González, Pedro Rodeiro Escobar, José Llópiz Castedo, María Díaz Vázquez, Flor de Lis Sánchez Juanas, María Villar Carballo, Marina Jara López Ribera, Manuella González Nunes, Samuel Rodríguez Zorrilla, and Avelino Rodríguez González.
• Servicio de Endocrinología y Nutrición, Hospital Montecelo, Pontevedra, España. Electronic address: angelmg88@hotmail.com.
• Med Clin (Barc). 2024 Jan 26; 162 (2): 565956-59.

ObjectivesTo assess the efficacy and safety of urea in patients with hyponatremia and heart failure (HF).Methods And ResultsThis is a retrospective observational analytical study of patients with HF and hyponatremia (Na+ <135mmol/L). Forty-nine patients treated with urea and 47 patients who did not receive urea, all under standard treatment (according to usual clinical practice) for HF, were included and followed up at Álvaro Cunqueiro Hospital in Vigo (Spain) between January 2013 and May 2022. The study evaluated the normalization of sodium levels (Na >135mmol/L). The initial natremia at the start of oral urea treatment was 127±5.22 mmol/L, at 24h the sodium level was 128±2.47 (P<.009), and the mean on the day of normalization was 135.19±4.23mmol/L (P<.005). The average number of days to achieve sodium normalization was 5.03±2.37 days. The initial uremia at the start of urea treatment was 73±46.93mg/dL, and the mean on the day of Na+ normalization was 116.05±63.64mg/dL (P<.002). The average oral urea dose was 22.5g/day. No relevant adverse effects were observed, nor were there significant changes in creatinine levels.ConclusionsOral urea treatment, when added to standard treatment for short periods of time, is safe and effective in correcting natremia in patients with hypervolemic HF with hyponatremia.Copyright © 2023 Elsevier España, S.L.U. All rights reserved.

17 keywords...

hide…